News for HTBX Stock

NightHawk Biosciences Provides First Quarter 2022 Business Update NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35 Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Market Open Today Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company’s Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments Heat Biologics’ Scorpion Subsidiary Announces Planned Development of New Kansas Commercial/Biodefense Biomanufacturing Facility Heat Biologics’ Announces Planned Investor and Media Livestream Event to Discuss Latest Developments Heat Biologics Unveils Enhanced Allogeneic Cell Manufacturing Process Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company Heat Biologics Provides Year-End 2021 Business Update Heat Biologics Announces Planned Transfer to the NYSE American Elusys Therapeutics Finalizes HHS Contract to Deliver ANTHIM®, Its Treatment for Inhalation Anthrax, to the U.S. Department of Health and Human Services Heat Biologics Announces New PTX-35 Preclinical Data in Organ Transplantation and Provides Update on HS-110 Heat Biologics Announces Planned Acquisition of Elusys Therapeutics Heat Biologics Unveils RapidVax®, A Novel Cellular Vaccine Platform Targeting Known and Unknown Emerging Biological Threats Heat Biologics Provides Third Quarter 2021 Business Update Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy Heat Biologics CEO to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29th Heat Biologics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Heat Biologics to Provide Corporate Update Heat Biologics Unveils Skunkworx Bio, New Drug Discovery Subsidiary Heat Biologics Announces Addition of Former US Senator Mark Pryor to Biothreat Advisory Board Heat Biologics Announces New Additions to Biothreat Advisory Board Heat Biologics Announces Formation of Biothreat Advisory Board Heat Biologics Provides Second Quarter 2021 Business Update Heat Biologics Announces Groundbreaking for New San Antonio Facility Heat Biologics Joins Russell Microcap® Index Heat Biologics Announces Significant Expansion of R&D and Pre-Clinical Capabilities at Corporate Headquarters Heat Biologics to Showcase Favorable Survival Data of HS-110 in Previously Treated Non-Small Cell Lung Cancer Patients at 2021 American Society of Clinical Oncology Annual Meeting Heat Biologics Announces Promising Survival Data of HS-110 in Two Treatment Settings of Lung Cancer; Selected for Presentation at 2021 American Society of Clinical Oncology Annual Meeting Heat Biologics Announces Multiple Presentations on PTX-35 at the Upcoming 3rd Annual Treg Directed Therapies Summit Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor Heat Biologics Provides First Quarter 2021 Business Update; Reports Continued Progress on Oncology and COVID-19 Vaccine Programs Heat Biologics Announces New Preclinical Data on PTX-35, Demonstrating Decreased Regulatory T-cell (Treg) Activity and Delayed Tumor Progression at American Association for Cancer Research (AACR) Annual Meeting 2021 Heat Biologic's COVID-19 Vaccine Demonstrates Robust T Cell Driven Immune Response to SARS-CoV-2 in Preclinical Studies Heat Biologics Provides Year-End Business Update Heat Biologics to Participate at M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference Heat Biologics to Present at 2021 BIO CEO & Investor Digital Conference Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial Heat Biologics Announces Publication of Additional Preclinical COVID-19 Vaccine Results Heat Biologics CEO to Participate in a Fireside Chat at the B. Riley Securities Oncology Investor Conference on Jan 21, 2021 Heat Biologics Commences Manufacturing Process for ZVX-60 Heat Biologics Promotes William L. Ostrander to Chief Financial Officer Heat Biologics to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference Heat Biologics Announces Completion of ZVX-60 Vaccine Cell Line for COVID-19 Heat Biologics Provides Business Update Heat Biologics Provides Third Quarter 2020 Business Update Heat Biologics Issued Additional Patent on gp96 Combination Platform Therapy with T-cell Co-Stimulator Heat Biologics CEO to Participate in Virtual Panel: "New Approaches to COVID-19: Hidden Breakthroughs," on Thursday, September 10th Heat Biologics Issued Key Patent on Combination Platform Therapy Heat Biologics Announces Publication of Preclinical COVID-19 Vaccine Results Heat Biologic's COVID-19 Vaccine Demonstrates Robust T Cell Driven Immune Response to SARS-CoV-2 in Preclinical Studies